@article{oai:nagoya.repo.nii.ac.jp:00021397,
 author = {Maeda, Osamu and Yokota, Kenji and Atsuta, Naoki and Katsuno, Masahisa and Akiyama, Masashi and Ando, Yuichi},
 issue = {1},
 journal = {Nagoya Journal of Medical Science},
 month = {Feb},
 note = {A 79-year-old man with lymph node recurrence of malignant melanoma received nivolumab, an antiprogrammed death 1 (PD-1) monoclonal antibody. He had pre-existing ocular myasthenia gravis (MG) and a continued small amount of corticosteroid. Grade 3 creatine phosphokinase elevation appeared after two doses of nivolumab, and the treatment was postponed until it improved to grade 1. After three doses of nivolumab, he experienced diplopia and facial muscle weakness which were consistent with an acute exacerbation of MG, and the symptoms relieved without additional treatment for MG. He achieved shrinkage of metastasis after ten doses of nivolumab. Although a case who died due to MG after administration of nivolumab was reported recently, pre-existing MG is considered not to be always a contraindication of nivolumab.},
 pages = {119--122},
 title = {Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis},
 volume = {78},
 year = {2016}
}